FILE PHOTO: The Merck emblem is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

Oct 14 (Reuters) – A panel of out of doors advisers to the U.S. well being regulator will meet late subsequent month to debate whether or not to authorize Merck & Co’s (MRK.N) experimental COVID-19 antiviral drug, the company mentioned on Thursday.

The U.S. Meals and Drug Administration’s (FDA) panel will meet on Nov. 30 to debate security and effectiveness of the drug, molnupiravir, for the therapy of mild-to-moderate COVID-19 in adults who’ve examined constructive and are at excessive danger for development to extreme sickness. (

The FDA usually follows the recommendation of its specialists however is just not sure to take action.

Merck earlier this week mentioned it filed for U.S. emergency use authorization for molnupiravir, which it’s growing with accomplice Ridgeback Biotherapeutics. The drug would turn into the primary oral antiviral remedy for COVID-19, if cleared by the company.

Pfizer Inc (PFE.N) and Swiss drugmaker Roche Holding AG (ROG.S) are additionally racing to develop an easy-to-administer antiviral tablet for the illness.

Merck’s therapy minimize the speed of hospitalization and demise by 50% in a trial of mild-to-moderately in poor health sufferers who had at the least one danger issue for the illness, in keeping with information launched earlier this month.

The corporate has a contract with the U.S. authorities to produce 1.7 million programs at a worth of $700 per course. The drugmaker additionally lately signed offers with Malaysia and Singapore for provide of the drug.

Bloomberg Information first reported on a U.S. FDA advisory committee assessment of the drug.

Reporting by Amruta Khandekar; Modifying by Maju Samuel and Shailesh Kuber

Our Requirements: The Thomson Reuters Trust Principles.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Live Updates COVID-19